SOLICITATION NOTICE
66 -- RNA Sample Prep Kit, Cycle Sequencing Kit and Small RNA Cluster Generation Kit v2-GAII
- Notice Date
- 9/2/2009
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90238-AV
- Archive Date
- 10/2/2009
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on a sole source basis an RNA Sample Prep Kit, Cycle Sequencing Kit and Small RNA Cluster Generation Kit v2-GAII from Illumina, Inc., 9885 Towne Centre Drive, San Diego, CA 92121. The services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13. The North American Industry Classification System Code is 325413 and the business size standard is 500 employees. The delivery date shall be two (2) weeks from date of award. To better characterize the molecular steps from HPV infections to precancer and from precancer to invasive cancer, the Study to Understand Cervical Cancer Early Endpoints and Determinants was launched in 2003. Within SUCCEED, gene expression profiling of HPV infected, precancerous and cancerous tissues are currently being performed using human and viral mRNA expression arrays. These analyses will allow the characterization of both human and viral gene expression profiles in cervical cancer progression. Recently, microRNAs (miRNA) have been described as important modulators of gene expression and were found to be significantly altered in various tumor entities. The NCI proposes to evaluate whether alterations of miRNA expression might affect risk for cervical cancer. The evaluation of miRNA expression will complement the on-going human and viral mRNA expression analyses and provide a detailed understanding of critical steps in cervical tissue transformation and in miRNA-dependent gene regulation. To profile the expression of miRNAs in the Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED) cervical tissue collection, the NCI has chosen to use Illumina's Solexa next generation sequencing platform. The advantage of next generation sequencing over microarray-based approaches is that it is not limited to analysis of known miRNAs and that it will allow the NCI to discover additional previously unknown host and viral miRNAs. In addition, direct miRNA sequencing will allow the NCI to identify nucleotide changes within the miRNA sequences that would remain unnoticed using microarray-based approaches. Among next generation sequencers, Illumina's Solexa Genome Analyzer is particularly well-suited for miRNA analysis because of its typical sequence read lengths of 36 nucleotides, i.e. it is highly compatible with the miRNA size range of 18-25 nucleotides. The Solexa output is quantitative because the system records the numerical frequency of each miRNA sequence in a given miRNA library population, thereby eliminating background signals due to hybridization that are common with the use of microarray-based approaches. The Illumina Solexa system is the only assay that can rapidly detect and quantify known and unknown host and viral RNAs from frozen tissue, and will allow the NCI to pursue etiologic research and biomarker discovery in SUCCEED. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can meet this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 11:00 a.m. ET on September 17, 2009. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to Ashley Virts at virtsa@mail.nih.gov. It is the vendor's responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please reference NCI-90238-AV on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90238-AV/listing.html)
- Record
- SN01937773-W 20090904/090903000910-9e48418c627a059b4ea72d4e61de8a54 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |